Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | TTR | P02766 | 1/20 | 0.49 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | JUN | P05412 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.42 |
| ▸ | ABAT | P80404 | 1/20 | 0.42 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.41 |
| ▸ | CFD | P00746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1088564 | 0.85 | JUN (0.44) | ALDH1A1TTRTSHRJUNNFKB1 | |
| SCHEMBL12996678 | 0.85 | PARP10 (0.45) | ALDH1A1TTRJUNNFKB1KDM4E | |
| SCHEMBL31190039 | 0.84 | JUN (0.57) | ALDH1A1AOX1TSHRJUNNFKB1 | |
| SCHEMBL320559 | 0.84 | JUN (0.57) | ALDH1A1AOX1TSHRJUNNFKB1 | |
| SCHEMBL3759591 | 0.84 | TTR (0.39) | ALDH1A1TTRAOX1TSHRJUN | |
| SCHEMBL11716701 | 0.81 | JUN (0.55) | ALDH1A1JUNNFKB1KDM4EHPGD | |
| SCHEMBL6022491 | 0.81 | AKR1C3 (0.61) | ALDH1A1TTRTSHRJUNNFKB1 | |
| SCHEMBL6022495 | 0.81 | AKR1C3 (0.61) | ALDH1A1TTRTSHRJUNNFKB1 | |
| SCHEMBL3362396 | 0.81 | PTGS2 (0.51) | ALDH1A1TTRJUNNFKB1KDM4E | |
| SCHEMBL11716698 | 0.81 | JUN (0.55) | ALDH1A1JUNNFKB1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE42700-E1 | Induction of apoptosis in cancer cells | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-09-13 | — | — | US | disclosed |
| CN-100348569-C | Induction of apoptosis in cancer cells | BURNHAM INST (US) | 2007-11-14 | — | — | CN | disclosed |
| US-7053071-B2 | For therapy of leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells | THE BURNHAM INSTITUTE (US) | 2006-05-30 | — | — | US | disclosed |
| CN-1659130-A | Induction of apoptosis in cancer cells | BURNHAM INST (US) | 2005-08-24 | — | — | CN | disclosed |
| EP-1456165-A1 | INDUCTION OF APOPTOSIS IN CANCER CELLS | The Burnham Institute (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20030176506-A1 | Induction of apoptosis in cancer cells | BURNHAM INSTITUTE FOR MEDICAL RESEARCH | 2003-09-18 | — | — | US | disclosed |
| WO-2003048101-A1 | INDUCTION OF APOPTOSIS IN CANCER CELLS | THE BURNHAM INSTITUTE (US) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176506-A1 | Induction of apoptosis in cancer cells | MCL1, BAD, BCL2 | ALDH1A1 1651/4885TTR 4544/4885AOX1 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.